Was PTC Therapeutics playing games when it tried to defuse the deflazacort controversy with a $35,000 annual price?
When PTC Therapeutics $PTCT CEO Stuart Peltz rolled out the biotech’s Q1 report this morning, he noted that company execs came up with what they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
